Last updated: September 27, 2026
Entocort EC is an oral controlled-release formulation of budesonide for mild-to-moderate Crohn's disease involving the ileum and/or ascending colon. Its commercial position has shifted from branded gastrointestinal product to mature generic market. The principal value drivers were controlled-release formulation technology, physician familiarity, and Crohn's disease demand. Those advantages weakened after U.S. generic budesonide capsule approvals and the expiration or loss of enforceability of key formulation patents.
What is Entocort EC and how does it work?
Entocort EC contains budesonide, a locally acting corticosteroid. The capsule uses an enteric-coated, controlled-release delivery system designed to delay drug release until the dosage form reaches the distal small intestine and proximal colon, the principal disease sites in its Crohn's disease indication.[1]
| Attribute |
Entocort EC |
| Active ingredient |
Budesonide |
| Dosage form |
Delayed-release oral capsule |
| U.S. strength |
3 mg capsule |
| Original developer |
AstraZeneca |
| U.S. indication |
Mild-to-moderate Crohn's disease involving ileum and/or ascending colon |
| Typical adult induction dose |
9 mg once daily for up to eight weeks |
| Maintenance indication |
Reduction of recurrence for up to three months after remission |
| Regulatory pathway |
New Drug Application, NDA 21-324 |
| Main commercial issue |
Generic delayed-release budesonide capsule competition |
Budesonide has high first-pass hepatic metabolism, which historically supported a lower systemic corticosteroid burden than prednisone. Entocort EC nevertheless carries corticosteroid risks, including adrenal suppression, infection risk, bone effects, and drug-interaction concerns.[1]
When did Entocort EC receive FDA approval?
The FDA approved Entocort EC in February 2001 under NDA 21-324.[2] The approval covered induction and maintenance treatment for Crohn's disease affecting the ileum and/or ascending colon.
Entocort EC regulatory timeline
| Date |
Event |
| February 2001 |
FDA approval of Entocort EC under NDA 21-324 |
| 2000s |
AstraZeneca commercialized Entocort in multiple international markets |
| 2008 |
AstraZeneca transferred U.S. rights to Prometheus Laboratories |
| 2011 |
Nestlé acquired Prometheus Laboratories |
| 2012 onward |
Generic delayed-release budesonide capsule competition developed in the U.S. |
| 2014 |
Salix Pharmaceuticals acquired by Valeant, later renamed Bausch Health |
| 2010s |
Brand and authorized-generic economics deteriorated as generic supply expanded |
| Current market |
Budesonide delayed-release capsules are available through multiple generic manufacturers |
AstraZeneca retained commercial interests in markets outside the U.S. for a period after transferring U.S. rights. Prometheus became the principal U.S. commercial rights holder before its acquisition by Nestlé.[3][4]
What patents protected Entocort EC?
The principal patent estate covered the formulation and controlled-release delivery of budesonide rather than the active ingredient itself. Budesonide is an old corticosteroid molecule, so product differentiation depended on release location, coating technology, dissolution behavior, and manufacturing controls.
Core U.S. patent protection
Public patent and litigation records identify U.S. Patent No. 6,458,356 as a central Entocort-related formulation patent. The patent concerned controlled-release pharmaceutical compositions containing budesonide and was asserted in ANDA litigation involving generic applicants.[5]
The Entocort estate included:
- Controlled-release budesonide compositions.
- Enteric-coating systems.
- Release profiles targeting the ileum and proximal colon.
- Manufacturing processes for coated multiparticulate or pellet dosage forms.
- Related formulation and method-of-use claims.
Patent protection was narrower than molecule-level exclusivity. A generic applicant could avoid infringement by developing a different coating, release profile, pellet architecture, or manufacturing process, provided its product still satisfied FDA bioequivalence requirements.
Orange Book status
The FDA Orange Book historically listed patents associated with Entocort EC and NDA 21-324. The most commercially relevant listings were formulation patents, not composition-of-matter patents.[2]
| Protection category |
Commercial relevance |
| Budesonide molecule patent |
No meaningful modern protection |
| Controlled-release formulation |
Primary historical barrier |
| Enteric coating and dissolution profile |
Relevant to ANDA design-around risk |
| Method-of-use claims |
Narrower protection tied to Crohn's disease treatment |
| Manufacturing patents |
Potential secondary barrier, often difficult to enforce against a non-infringing process |
The commercial impact of Entocort's patent estate declined as the key U.S. formulation patents approached expiration and generic applicants obtained FDA approval. The effective loss of exclusivity occurred through a combination of patent expiry, litigation outcomes, and regulatory approval of competing products rather than through a single molecule-patent event.
When did Entocort EC lose exclusivity?
Entocort EC lost meaningful U.S. exclusivity during the early-to-mid 2010s. The principal formulation protection was scheduled to expire in the 2010s, with any pediatric extension or regulatory exclusivity providing only limited additional protection.[2][5]
The important commercial date is the first approved generic delayed-release budesonide capsule, not only the nominal expiration date of an individual patent. Once generic applicants obtained approval, pharmacy substitution and payer pressure reduced branded pricing even where residual patents or regulatory protections remained.
Exclusivity analysis
| Exclusivity type |
Entocort EC position |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
Not the principal commercial protection |
| Pediatric exclusivity |
Limited and temporary, if applicable to the relevant approval |
| Formulation patents |
Expired or no longer commercially decisive |
| Method-of-use patents |
Narrow, with limited ability to preserve broad market exclusivity |
| Current barrier to generic entry |
Low |
Entocort does not have the protection profile of a biologic or a small-molecule product with a durable composition-of-matter patent. The product's remaining commercial value is therefore concentrated in brand prescribing, supply reliability, contracting, and niche patient or physician preferences.
Which companies challenged Entocort EC patents?
Generic companies pursued ANDA pathways for budesonide delayed-release capsules. Public litigation records identify Apotex among the generic applicants involved in disputes concerning Entocort-related patents.[5]
Potential generic challengers and later suppliers included companies active in oral solid-dose products, including:
- Apotex.
- Mylan, now part of Viatris.
- Teva Pharmaceuticals.
- Sandoz.
- Actavis, later part of Teva or Allergan-related corporate structures depending on the relevant period.
- Other FDA-approved suppliers of budesonide delayed-release capsules.
Paragraph IV litigation
An ANDA applicant may file a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The filing can trigger Hatch-Waxman litigation and a statutory 30-month stay of FDA approval, subject to statutory exceptions.[6]
Entocort-related litigation centered on whether the generic formulation infringed the asserted controlled-release claims and whether those claims were valid. The key legal questions included:
- Whether the generic product used the claimed release architecture.
- Whether the claimed formulation was obvious in view of prior art.
- Whether the branded patent holder could prove infringement from publicly available product information.
- Whether a generic design-around could meet the same therapeutic delivery objective without infringing the claims.
Generic litigation reduced the practical life of the brand's franchise even before all commercial sales transferred to generics. Once a credible Paragraph IV challenge reached the market, branded forecasts typically incorporated earlier erosion, litigation expense, and possible authorized-generic exposure.
What was the financial trajectory of Entocort EC?
Entocort generated peak annual sales in the low hundreds of millions of dollars, supported by Crohn's disease prevalence, limited oral steroid alternatives, and premium pricing for the controlled-release formulation. Public-company reporting did not consistently provide a single comparable global revenue series across all ownership periods because rights changed between AstraZeneca, Prometheus, Nestlé, and later commercial organizations.[3][4][7]
Financial trajectory by period
| Period |
Financial position |
Main driver |
| 2001-2005 |
Launch and expansion |
FDA approval, specialist adoption, limited direct competition |
| 2006-2009 |
Growth to mature branded product |
Crohn's disease demand and international sales |
| 2010-2012 |
High-revenue maturity |
Strong U.S. and international brand contribution before broad generic erosion |
| 2013-2015 |
Decline |
Generic approvals, payer substitution, patent expiry pressure |
| 2016 onward |
Mature generic market |
Lower prices, multiple suppliers, limited brand leverage |
AstraZeneca's annual reports identified Entocort as a significant gastrointestinal product before the U.S. rights transfer. Prometheus treated the product as part of its gastroenterology franchise, while Nestlé's acquisition of Prometheus shifted the asset into a broader medical-nutrition and specialty-pharma portfolio.[3][4]
The major financial inflection point was the transition from single-brand economics to multisource generic economics. Revenue loss occurred through several channels:
- Lower average selling price.
- Pharmacy substitution.
- Formulary preference for generic budesonide.
- Reduced promotional return.
- Increased rebate pressure.
- Inventory and channel destocking during generic entry.
- Loss of leverage in specialty-pharmacy contracting.
A branded version can retain residual revenue after generic launch, especially where physicians specify the brand or where supply interruptions affect generics. That residual revenue is generally too small to support the pre-generic commercial infrastructure.
How does Entocort EC compare with competing Crohn's disease drugs?
Entocort EC occupies a narrower treatment position than systemic corticosteroids, immunomodulators, and biologics.
| Product class |
Examples |
Position relative to Entocort EC |
| Conventional systemic corticosteroid |
Prednisone |
Broader systemic effect, generally greater toxicity burden |
| Controlled-release corticosteroid |
Budesonide delayed-release capsules |
Direct generic substitute for Entocort EC |
| Immunomodulator |
Azathioprine, 6-mercaptopurine |
Slower onset and different maintenance role |
| Anti-TNF biologic |
Infliximab, adalimumab |
Used for more extensive or refractory disease |
| Integrin antagonist |
Vedolizumab |
Advanced therapy for moderate-to-severe disease |
| IL-12/23 or IL-23 therapy |
Ustekinumab, risankizumab |
Higher-cost advanced therapies |
| JAK or other targeted therapy |
Varies by indication and jurisdiction |
Increasing competition in later-line disease |
Entocort is most vulnerable to generic substitution within the oral budesonide segment. It is less directly threatened by biologics because treatment intensity differs. The relevant commercial comparison is not only Entocort versus biologics. It is Entocort versus prednisone, generic budesonide, and newer low-systemic-exposure steroid formulations.
What formulation patents remain important for budesonide products?
Formulation patents remain relevant for new budesonide products with different delivery targets or indications. A new product may seek protection for:
- Release in the colon rather than the ileum.
- Extended or multi-site release.
- Tablet rather than capsule delivery.
- Combination therapy.
- Pediatric dosing.
- Alternative inflammatory bowel disease indications.
- Improved stability or reduced food effect.
- Specific particle size or coating composition.
These patents do not automatically restore exclusivity to Entocort EC. They protect the later product only if the claims cover a commercially meaningful technical feature and withstand validity and infringement challenges.
The strongest potential formulation claims are those tied to measurable product characteristics, such as dissolution at defined pH levels, release timing, coating composition, or pharmacokinetic performance. Broad claims that merely recite oral budesonide delivery face greater prior-art and obviousness pressure.
What is the FDA status of generic budesonide capsules?
FDA-approved generic products use the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug. The relevant dosage form is a delayed-release capsule containing budesonide.[2]
Generic approval does not require a new clinical efficacy program equivalent to the original NDA. The generic must meet manufacturing, quality, labeling, and bioequivalence requirements. This lowers development cost and accelerates competition after patent barriers fall.
The key regulatory distinction is between:
- Budesonide delayed-release capsules for Crohn's disease.
- Budesonide extended-release tablets or capsules for other gastrointestinal indications.
- Budesonide inhalation products for asthma or chronic obstructive pulmonary disease.
- Budesonide nasal products.
These products are not automatically interchangeable. Delivery site, formulation, route of administration, and FDA labeling determine the relevant market.
What generic launch risks exist for Entocort EC?
The generic launch risk is high because the product has:
- An old active ingredient.
- A mature clinical market.
- A well-defined reference product.
- A standard oral dosage form.
- Several potential generic manufacturers.
- No durable composition-of-matter patent.
- Limited ability to differentiate the branded product clinically.
The principal launch scenarios are:
| Scenario |
Market outcome |
| One approved generic |
Moderate price erosion and partial brand retention |
| Several approved generics |
Rapid price compression and pharmacy substitution |
| Authorized generic plus independent generics |
Faster transfer of volume from the branded product |
| Supply-constrained generic market |
Temporary brand or secondary-supplier retention |
| New delivery technology |
Segmentation rather than direct replacement |
Manufacturing remains a secondary barrier. Delayed-release budesonide capsules require controlled coating, dissolution testing, content uniformity, and stability control. Those requirements create execution risk but do not normally prevent experienced generic manufacturers from entering.
What licensing deals affected Entocort EC?
The major commercial transactions were rights transfers and corporate acquisitions rather than technology licenses.
| Transaction |
Effect on Entocort |
| AstraZeneca to Prometheus |
Transferred U.S. commercial rights |
| Nestlé acquisition of Prometheus |
Moved Prometheus assets, including Entocort rights, into Nestlé's specialty-pharma portfolio |
| Later specialty-pharma restructuring |
Reduced strategic importance as generic competition expanded |
These transactions changed revenue ownership and reporting visibility. They also complicate historical sales comparisons because one company may report global product sales while another reports only U.S. net sales or portfolio-level revenue.[3][4]
What is the current commercial value of Entocort EC?
Entocort EC's current value is primarily as a mature prescription product and reference brand. Its historical franchise value came from premium pricing before generic entry. Current value is constrained by:
- Generic substitution.
- Low switching costs for payers.
- Limited brand differentiation.
- Expired or weakened formulation exclusivity.
- Competition from other steroid and advanced therapies.
- Reduced promotional return.
The remaining strategic value can include brand recognition, established manufacturing know-how, supply continuity, and physician familiarity. Those factors may support a niche brand business but do not recreate the original exclusivity economics.
How strong is the Entocort patent estate?
The patent estate was commercially meaningful before generic entry but is weak as a present-day barrier.
| Factor |
Assessment |
| Active ingredient protection |
Weak or expired |
| Formulation protection |
Historically important; now expired or commercially limited |
| Method-of-use protection |
Narrow |
| Manufacturing protection |
Potentially relevant but difficult to use against all suppliers |
| Patent term remaining |
No meaningful broad U.S. exclusivity |
| Generic design-around risk |
High |
| Litigation leverage |
Low after market entry |
| Overall current patent strength |
Low |
Key Takeaways
- Entocort EC is a delayed-release budesonide capsule approved by the FDA in 2001 for ileal and ascending-colon Crohn's disease.
- Its commercial protection depended on formulation and controlled-release patents, not a durable budesonide molecule patent.
- U.S. rights moved from AstraZeneca to Prometheus and later into Nestlé through the Prometheus acquisition.
- The product reached mature annual sales in the low hundreds of millions of dollars before generic erosion.
- Generic competition became the decisive market event during the early-to-mid 2010s.
- Current generic-entry risk is high and current broad patent strength is low.
- Future value depends on supply, contracting, brand retention, and differentiated budesonide delivery technologies rather than Entocort EC exclusivity.
FAQs About Entocort EC Patent and Market Exposure
Is Entocort EC still protected by a composition-of-matter patent?
No. Entocort's commercial protection was based primarily on controlled-release formulation technology. The budesonide active ingredient is not protected by a modern composition-of-matter patent that could block generic delayed-release capsules.
Is generic budesonide the same as Entocort EC?
Generic delayed-release budesonide capsules are intended to be therapeutically equivalent to the FDA reference product when approved through the ANDA pathway. Product-specific labeling, manufacturer, supply, and inactive ingredients can differ.
Can a company launch a new budesonide product without infringing Entocort patents?
Potentially. A company may design around expired or enforceable formulation claims by using a different dosage form, coating, release profile, manufacturing process, or delivery site. The analysis depends on the claims and the product's technical characteristics.
Does Entocort EC compete directly with biologic Crohn's disease treatments?
Usually not on a direct treatment-intensity basis. Entocort is mainly used for localized mild-to-moderate ileal or right-colon disease, while biologics generally address moderate-to-severe or refractory disease. The closer competitors are generic budesonide and systemic corticosteroids.
Are Entocort EC sales still separately disclosed?
Not consistently. Ownership changes and portfolio reporting have reduced the availability of comparable standalone revenue figures. Current economics are better assessed through generic availability, pricing, prescription volume, and payer substitution than through historical brand sales.
References
- U.S. Food and Drug Administration. (2023). Entocort EC (budesonide) delayed-release capsules prescribing information.
- U.S. Food and Drug Administration. (2024). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations.
- AstraZeneca. (2008). Annual report and Form 20-F.
- Nestlé S.A. (2011). Annual review and financial statements.
- AstraZeneca LP v. Apotex Corp., 633 F. Supp. 2d 1018 (D. Del. 2009).
- U.S. Food and Drug Administration. (2024). Hatch-Waxman Amendments and abbreviated new drug applications.
- Bausch Health Companies Inc. (2014). Annual report and Form 10-K.
